Spots Global Cancer Trial Database for Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer
Official Title: Phase I Study of M2ES Combined Gemcitabine in Patients With Advanced Pancreatic Cancer
Study ID: NCT01218880
Conditions
Study Description
Brief Summary: Phase I trail will be conducted to evaluate the safety of M2ES in combination with gemcitabine in locally advanced or metastatic pancreatic cancer.
Detailed Description: Phase I trail will be conducted to determine the MTD and safety of M2ES(administered intravenous infusion on Days 1,8,15,21of a 28-day cycle) in combination with gemcitabine (1000 m/m2). Gemcitabine will be administered as an intravenous infusion on Days 1, 8, and 15 of each 28-day cycle,at the same time determine the safety and efficiency of this combined regime.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Shanghai Changhai Hospital, Shanghai, Shanghai, China
Contact Details
Name: Zhaosheng Li, MD
Affiliation: Shanghai Changhai Hosptial
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
